Harrow Health (NASDAQ:HROW) is set to post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Harrow Health to post earnings of $0.12 per share for the quarter.
Harrow Health (NASDAQ:HROW) last posted its quarterly earnings results on Tuesday, March 12th. The company reported $0.77 EPS for the quarter, missing the consensus estimate of $0.84 by ($0.07). Harrow Health had a net margin of 35.35% and a return on equity of 177.27%. The company had revenue of $11.38 million for the quarter, compared to analysts’ expectations of $10.92 million. On average, analysts expect Harrow Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of Harrow Health stock traded up $0.01 on Tuesday, hitting $4.71. 2,122 shares of the company traded hands, compared to its average volume of 148,042. The company has a quick ratio of 2.61, a current ratio of 2.76 and a debt-to-equity ratio of 0.48. Harrow Health has a 12-month low of $1.99 and a 12-month high of $7.20. The stock has a market cap of $112.40 million, a P/E ratio of 7.72 and a beta of -0.02.
Several equities analysts have recently commented on the stock. TheStreet upgraded shares of Harrow Health from a “d-” rating to a “c” rating in a report on Wednesday, May 1st. Zacks Investment Research upgraded shares of Harrow Health from a “sell” rating to a “buy” rating and set a $6.00 price target on the stock in a report on Friday, March 15th. Finally, ValuEngine cut shares of Harrow Health from a “hold” rating to a “sell” rating in a report on Wednesday, March 27th.
In related news, Director Robert J. Kammer sold 10,000 shares of Harrow Health stock in a transaction on Monday, April 1st. The shares were sold at an average price of $4.77, for a total value of $47,700.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders sold 30,000 shares of company stock valued at $162,500. 12.43% of the stock is owned by company insiders.
About Harrow Health
Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.
Recommended Story: What strategies should day traders use to execute a trade?
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.